M. C. Nussenzweig

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity

This study examines how SARS-CoV-2 spike glycosylation affects viral function and neutralization sensitivity to antibodies.

CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals

This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain

The paper shows that antigen presentation dynamics after multiple vaccinations influence the immune response to SARS-CoV-2 Omicron by shaping B cell responses and antibody targeting of epitopes.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape

The paper shows that epistasis reduces the genetic barrier for SARS-CoV-2 variants to escape broadly neutralizing antibodies by enabling resistance through combinations of mutations.

Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection

This study compares memory B cell responses after Delta and Omicron BA.1 breakthrough infections versus mRNA vaccine doses, finding that Delta infection boosts overall memory B cell potency and breadth, while Omicron infection only enhances strain-specific responses.

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens

This study compares humoral immune responses to different SARS-CoV-2 vaccination regimens, finding differences in antibody and memory B cell responses and neutralizing breadth against variants.

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine

This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.

HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design

The paper uses cryo-EM to study germline antibody-Env structures to identify key interactions and guide vaccine design.

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation

This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.

Distinct gene expression by expanded clones of quiescent memory CD4+ T cells harboring intact latent HIV-1 proviruses

HIV-1 Vpu restricts Fc-mediated effector functions in vivo

This study shows that HIV-1 Vpu reduces nnAb recognition and ADCC resistance, with nnAb Fc-effector functions dependent on Env's open conformation.

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins

The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies

The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.

Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope

This study identifies an off-target antibody that displaces the HIV-1 Env fusion peptide and blocks neutralizing epitopes, providing insights for vaccine design.

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

This study evaluates combination therapies of remdesivir and monoclonal antibodies for SARS-CoV-2 and its B.1.351 variant in mice, showing improved outcomes with the antibody combination.

Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease

Persistent Cellular Immunity to SARS-CoV-2 Infection

The paper shows that SARS-CoV-2 infection leads to persistent, functional memory T cell responses and enduring immune alterations in CD4+ and CD8+ T cells six months post-infection.

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

The paper demonstrates that mosaic nanoparticles displaying multiple coronavirus RBDs induce cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses in mice.

Evolution of Antibody Immunity to SARS-CoV-2

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

Sequence evaluation and comparative analysis of novel assays for intact proviral HIV-1 DNA

This study compares two novel assays, IPDA and Q4PCR, for measuring intact HIV proviral DNA in ART-suppressed individuals, finding significant differences in their frequency estimates.

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates

This study evaluates the neutralizing activity of 9 anti-HIV-1 bNAbs against primary African isolates, finding reduced potency and breadth compared to pseudotyped viruses.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

A Broadly Neutralizing Macaque Monoclonal Antibody Against the HIV-1 V3-Glycan Patch

This paper reports a broadly neutralizing monoclonal antibody from a macaque infected with SHIVAD8 that targets the V3-glycan patch of HIV-1 Env, showing neutralizing activity and protective efficacy in vivo.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.